Cipla Ltd — Q4 FY26
Cipla delivered a strong Q4 FY26 with India business growing 15% YoY and North America revenue of $155M.
bullish
high
✓ Verified against BSE filing
Claim Ledger
Did management answer the analysts?
Every material analyst question, graded on whether management actually answered it — with the verbatim exchange and quantitative claims checked against filed numbers.
75%Questions answered0Evaded / deflected10Questions auditedContradictedNumbers vs filing
Answered
Medium priority
Did you book any shelf stock adjustment for Rev?
Asked by Vishal Mandanda, Systematics
Directly answered no with reference to prior quarter.
Read the exchange
Question
During the quarter, did we uh kind of book any shelf stock adjustment for Reb?
Management (unidentified)
Uh no, I think we had shared this in the last quarter as well. We did not have any SSA adjustment.
Answered
High priority
Impact of innovator launching green version of Ventolin?
Asked by Vishal Mandanda, Systematics
Provided clear reasoning on regulatory process and no near-term impact.
Read the exchange
Question
If the innovator is able to replace all of their Ventolin product with the new version, would that impact Cipla?
Management (unidentified)
Uh right generic to the existing Ventolin... switching to another variant is a process which is not an automatic process under the US law at this point of time. So we do not anticipate any near-term impact.
Partial answer
High priority
Update on respiratory pipeline: Advair, Synagis, Qvar, Flovent?
Asked by Vishal Mandanda, Systematics
Gave general timing but no specific dates or details on each asset.
no specific datesvague timing
Read the exchange
Question
If you could update on the respiratory pipeline, the key assets: Advair, Synagis, Qvar, Flovent?
Management (unidentified)
As we had guided, we were expecting four approvals this year. Ventolin has already got approved. During the year we are expecting Advair and then one other asset to get approved. This will happen during H1 and one is H2 as well.
Answered
High priority
What is holding back Advair for so long?
Asked by Vishal Mandanda, Systematics
Explained the reason and current status clearly.
Read the exchange
Question
What is holding back Advair for so long?
Management (unidentified)
We had an OAI at our Indore facility. So we had to take transfer to the US which caused the delay. But now we're ready with everything. It's just a matter of receiving just one final one. We've been through a pre-approval inspection on our US facilities for this particular product.
Answered
Low priority
Benefit from EU FTA for respiratory portfolio?
Asked by Vishal Mandanda, Systematics
Directly stated no meaningful impact and explained why.
Read the exchange
Question
Do you expect to see any benefit out of the EU FTA for your respiratory portfolio because you source a lot of the basic devices from Europe?
Management (unidentified)
At this point, we're not expecting any meaningful impact of that. It's more business as usual. There is no benefit as such and in EU we already sell respiratory devices which are in-house.
Evasive
Low priority
Specific AI initiatives and scaling plans?
Asked by Sedart Nandhi, CWC
Spoke generally about AI but gave no concrete initiatives or pilots.
no specific examplesvague description
Read the exchange
Question
If you could share any specific initiatives that you've taken and any pilot initiatives that you see scaling up in future.
Management (unidentified)
AI is a broad-based implementation targeting multiple functions... implementations across quality, regulatory, corporate functions, and R&D related use cases. The idea is to use it for faster decision making and productivity benefits.
Answered
High priority
Biosimilars strategy: in-licensing or own development?
Asked by Sedart Nandhi, CWC
Provided clear strategy, pipeline numbers, and timeline.
Read the exchange
Question
In terms of your strategy for biosimilars, are you looking at in-licensing or your own development and what sort of pipeline and timeline?
Management (unidentified)
We have predominantly an in-house strategy with two assets under development for developed markets. One is already under clinical trial under an IND in US. We will be adding one to two assets each year, resulting in a pipeline of 6 to 8 in-house assets over the next 5 to 8 years. We are also considering limited in-licensing for near-term opportunities.
Partial answer
High priority
Bridge to $1bn US revenue run rate by end of FY27?
Asked by SuryaR, Philip Capital
Explained run rate vs revenue but did not provide a detailed bridge.
no product-level breakdownvague timing
Read the exchange
Question
What is the kind of bridge that you are talking about where from this revenue buildup that will happen? Can you give some clarity?
Management (unidentified)
The guidance is a billion dollar run rate by the end of the year, not revenue during the year. It's contingent on pipeline maturing. We have one approval already, three other respiratory approvals, one big peptide approval, and three other products. As these get approved, run rate will improve to that billion by end of FY27.
Partial answer
High priority
Outlook for lanreotide given disruption?
Asked by SuryaR, Philip Capital
Provided some details but deferred exact timeline to next quarter.
deferred to next quarterno specific timeline
Read the exchange
Question
What is the outlook that we are giving for lanreotide for this year and subsequent period given the kind of total disruption?
Management (unidentified)
The partner is working on remediation. By next quarter we'll have closer visibility. We have also identified an alternate supplier based out of US. Objective is to file by early next calendar year or Q4 of this financial year. It will be back definitely from FY28 perspective.
Answered
High priority
Impact of new Ventolin variant on market dynamics?
Asked by SuryaR, Philip Capital
Clearly explained product differentiation and expected market share gain.
Read the exchange
Question
With another variant of albuterol getting approved, do you find any changes to market dynamic in terms of pricing or competition or scope?
Management (unidentified)
These are different products with different NDC, different market. We have CGT on generic Ventolin, so we will be exclusive for 6 months. No cannibalization on the other variant. We're more likely to take share from existing Ventolin suppliers.
Partial answer
Medium priority
Why is R&D spend high despite few ANDA filings?
Asked by Tshar Manutani, Motilal Oswal Financial Services
Explained reasons but declined to provide per-ANDA cost.
no per-filing numbervague on breakdown
Read the exchange
Question
R&D spend overall almost 2,000 crores but very few ANDAs filed. Is R&D spend per ANDA significantly higher?
Management (unidentified)
We have gone up including some on oligonucleotide side. More respiratory, peptide, oligo resulting in higher spend per filing. Some involve litigation cost. Hard to put a metric per filing because nature changes. We are guiding towards 7%ish R&D spend as a percentage of sales.
Partial answer
High priority
Visibility and risk mitigation for US $1bn exit run rate?
Asked by Damian Kerai, HSBC
Gave some progress updates but lacked specific risk mitigation details.
no specific GDUFA datesvague on risk mitigation
Read the exchange
Question
What kind of visibility you have on these products which gives you confidence that you can receive approval this year? And what risk mitigation strategies have you implemented?
Management (unidentified)
In terms of confidence, we are seeing developments: for Advair we had a PAI, Ventolin got approval. We are aware of GDUFA dates for some. From facility point of view, all facilities are ready. We don't anticipate risks in facility; Goa recently got inspected with two observations, we've responded.
Quantitative claims vs filed numbers
| Claim | Management said | Filing | Verdict |
|---|---|---|---|
| EBITDA margin guidance of 18.5% to 20% for FY27 | 18.5% | 15% | Overstated vs filing |
| US revenue annualized $620 million in Q4 FY26 | 62,00,00,000 | 6,541 | Overstated vs filing |
Filed figures sourced from Screener.in. Claims within a small tolerance of the filing are marked “matches filing”.